Developer docs
API playgroundTry for free, no card

Search company profiles

Adium México

Full company profile

uuid00vjp7k

Namestring
Adium México
Legal namestring
Asofarma de México, S.A. de C.V.
Websiteurl
adium.com.mx
Company typeenum
Private
Founded yearint
1974
Descriptiontext

Adium México (legal entity Asofarma de México, S.A. de C.V.) is a Mexico-based pharmaceutical laboratory that develops, manufactures, and commercializes branded prescription medications across 15 therapeutic areas, including cardiology, diabetes, oncology, neurology, rare diseases, immunology, gastroenterology, gynecology, psychiatry, and urology. The company operates as the Mexican subsidiary of Grupo Adium, a Latin American pharmaceutical conglomerate with presence in 18 countries, 7,000+ collaborators, and five GMP-certified manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay producing 120+ million units annually. Grupo Adium is recognized as the sixth-largest pharmaceutical company in Latin America. Adium México also operates Adium Pro, a wholly-owned digital platform providing medical-scientific courses, clinical cases, webinars, and events to healthcare professionals.

The company pursues a dual business model: (1) proprietary and branded pharmaceutical product sales, including combination therapies and branded generics such as Tavor CR, Vesicare, Iltux, Tafirol, and Vartalon Compositum, distributed through authorized pharmacies and healthcare institutions; and (2) long-term licensing and distribution agreements with more than 10 multinational biotech and innovation companies (PharmaMar, Y-mAbs, BeiGene, Jazz Pharmaceuticals, Astellas Pharma, Debiopharm, and others), positioning Adium as the partner of choice for foreign innovators seeking pan-Latin American market access. Go-to-market is enterprise field sales via a specialized sales force targeting healthcare professionals and institutions, supported by a restricted-access healthcare professional portal, medical congresses, email marketing, and organic social channels. Manufacturing is governed by Quality by Design, GMP/GLP/GDP practices, and a pharmacovigilance system aligned with EMA and USFDA guidelines. In May 2024, the Mexican entity rebranded from Asofarma de México to Adium México to align with the broader Grupo Adium brand; the legal entity and operations remained unchanged.

Short descriptiontext

Adium México (legal entity Asofarma de México, S.A. de C.V.) is a pharmaceutical laboratory that develops, manufactures, and distributes branded prescription medications across 15 therapeutic areas, serving healthcare professionals and patients in Mexico as part of Grupo Adium, a Latin American pharmaceutical group operating in 18 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersMéxico, Colombia
HQ citystring
México
HQ countrystring
Colombia
HQ regionstring
Latin America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, prescription medications, therapeutic products, healthcare distribution, biotech licensing
Industry1 code
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Sale of proprietary and licensed pharmaceutical products across multiple therapeutic areas including cardiology, diabetes, oncology, and rare diseases

adium.com.mx
2Licensing and Distribution
TypeLicensing Royalties
Description

Licensing agreements with global biotech and innovation companies for promotion and distribution of their products throughout Latin America

adium.com.mx
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details1 tier
1Prescription pharmaceutical products
ModelOtherBilling cadenceOther
Notes

Products are prescription medications; pricing not publicly disclosed on website; access restricted to registered healthcare professionals

adium.com.mx
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adium México is a pharmaceutical laboratory that develops, manufactures, and commercializes a broad portfolio of prescription medications across 15 therapeutic areas including cardiology, diabetes, oncology, rare diseases, neurology, and gynecology. The company distributes both proprietary products and those licensed from global biotech partners to healthcare professionals and institutions in Mexico, supported by a specialized sales force, GMP-certified manufacturing, and pharmacovigilance systems aligned with international regulatory standards.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 42% of waste recycled in 2023
+3 more records
Product overview1 text field

Adium México is a pharmaceutical laboratory offering a broad portfolio of therapeutic products organized across 15 therapeutic areas: Cardiology, Diabetes, Analgesia, Rare Diseases, Gastroenterology, Gynecology, Hematology, Immunology, Neurology, Obesity, Oncology, Osteoarticular, Osteoporosis, Psychiatry, and Urology. The company also operates Adium Pro, a digital platform for medical-scientific content. Products include both branded medications (Tavor CR, Vesicare, Iltux, Tafirol, Vartalon, etc.) and combination therapies. The portfolio spans over 50 years of experience, offering innovative and high-quality therapeutic solutions to physicians and patients in Mexico and Latin America.

Product and service6 records
1Cardiology Portfolio
CategoryTherapeutic Area - Cardiovascular
Description

Pharmaceutical products for the treatment of hypertension, hypercholesterolemia, and anticoagulation, addressing cardiovascular disease as a leading cause of death in Latin America. Prescribed by cardiology specialists.

2Diabetes Portfolio
CategoryTherapeutic Area - Endocrinology
Description

Products for treatment of Diabetes Type I and Type II, addressing a leading cause of death and disability in Latin America. Includes combination therapies such as Vidagliptina/Metformina.

3Oncology Portfolio
CategoryTherapeutic Area - Oncology
Description

Broad portfolio of medications for different types of cancer affecting lung, breast, pancreas, and bile ducts, including tamoxifen-based therapy. Distributed through licensing partnerships with global biotech companies.

4Rare Diseases Portfolio
CategoryTherapeutic Area - Rare Diseases
Description

Medicines for rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis.

5Adium Pro
CategoryDigital Platform - Medical Education
Description

Medical-scientific content platform for healthcare professionals providing access to courses, articles, clinical cases, events, webinars, and continuing medical education resources.

6Licensing and Distribution Partnerships
CategoryLicensing Services - Regional Commercialization
Description

Long-term licensing and distribution agreements with over 10 multinational biotech and innovation companies including PharmaMar, Y-mAbs, BeiGene, Jazz Pharmaceuticals, Astellas Pharma, and Debiopharm, enabling promotion and distribution of their innovative products across Latin America.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing agreement for innovative pharmaceutical products, enabling distribution of advanced therapies in Latin America through Adium's regional presence and commercial capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing partnership for pediatric oncology and other specialty therapeutic areas, leveraging Adium's regional commercial infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global biotech partnership for innovative oncology treatments, distributed through Adium's commercial network across Latin America.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing partnership for specialty pharmaceuticals, utilizing Adium's market access expertise and regulatory capabilities in the region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for innovative pharmaceutical products, leveraging Adium's regional presence and specialized sales force.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing partnership for specialty therapeutics, distributed through Adium's established commercial channels in Latin America.

7Additional Global Innovation Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Adium holds long-term licensing agreements with more than 10 multinational innovation companies, positioning the company as the partner of choice for pharmaceutical expansion into Latin America.

adium.com.mx
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sanofi is a global pharmaceutical incumbent operating in cardiovascular, diabetes, oncology, rare disease and vaccines across Latin America. Comparable as a broad-portfolio competitor in the same therapeutic categories Adium addresses, though at materially larger scale and with proprietary global R&D.

2Eurofarma Laboratórios
TypeDirect peer
Description

Eurofarma is a Brazilian privately held pharmaceutical company with manufacturing operations across Latin America and a portfolio spanning multiple therapeutic areas including specialty, generics and OTC — directly comparable to Adium México in scale, LatAm geographic footprint, and broad-therapeutic-area pharmaceutical commercialization model.

TypeDirect peer
Description

Bagó is an Argentine-founded multinational pharmaceutical group with operations across Latin America, manufacturing branded specialty and OTC products. Its pan-regional LatAm manufacturing and commercial model is closely comparable to Adium's group-level footprint.

TypeDirect peer
Description

Aché is a top-five Brazilian pharmaceutical company with branded generics, prescription, and OTC products plus a meaningful oncology franchise. Like Adium, Aché operates manufacturing in multiple Latin American countries with multi-therapeutic-area coverage and is a comparable regional scale player.

5Laboratorios Liomont
TypeRegional player
Description

Liomont is a Mexican pharmaceutical manufacturer of branded generics and specialty products, operating mainly in Mexico but exporting regionally. It is comparable to Adium México on therapeutic-area breadth and Mexico-centric manufacturing, though smaller in geographic reach.

TypeDirect peer
Description

EMS is one of the largest Brazilian pharmaceutical manufacturers with leading market share in Brazil and a broad generics-plus-branded portfolio. It is a direct competitor to Adium in the Latin American prescription pharmaceutical market, particularly in Brazil and cross-border specialty categories.

TypeDirect peer
Description

Biolab is a Brazilian specialty pharmaceutical company with strong presence in cardiology, women's health and central nervous system therapeutics. Its therapeutic mix, LatAm regional focus and licensing-driven growth model closely resemble Adium's strategy.

TypeRegional player
Description

Genomma Lab is a Mexico-headquartered pharmaceutical company listed on the Mexican Stock Exchange with a portfolio spanning OTC, personal care and branded generics across Latin America. It is the most direct publicly traded Mexican pharma comparable to Adium México in therapeutic breadth and LatAm commercial footprint.

TypeDirect peer
Description

Siegfried is a Swiss pharmaceutical manufacturer specializing in contract development and manufacturing for branded and generic drugs globally, including Latin America. Comparable to Adium in the manufacturing-for-license-partners and finished-dose pharmaceutical production model.

TypeBroad incumbent
Description

Novartis is a global branded pharmaceutical incumbent with an established commercial presence across Latin America, overlapping with Adium in cardiology, oncology, neurology and immunology therapeutic areas. It competes broadly but is not specialty-focused on the LatAm mid-tier market Adium targets.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adium México

Pharmaceutical Manufacturingadium.com.mx

Adium México (legal entity Asofarma de México, S.A. de C.V.) is a pharmaceutical laboratory that develops, manufactures, and distributes branded prescription medications across 15 therapeutic areas, serving healthcare professionals and patients in Mexico as part of Grupo Adium, a Latin American pharmaceutical group operating in 18 countries.

What Adium México does

Adium México (legal entity Asofarma de México, S.A. de C.V.) is a Mexico-based pharmaceutical laboratory that develops, manufactures, and commercializes branded prescription medications across 15 therapeutic areas, including cardiology, diabetes, oncology, neurology, rare diseases, immunology, gastroenterology, gynecology, psychiatry, and urology. The company operates as the Mexican subsidiary of Grupo Adium, a Latin American pharmaceutical conglomerate with presence in 18 countries, 7,000+ collaborators, and five GMP-certified manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay producing 120+ million units annually. Grupo Adium is recognized as the sixth-largest pharmaceutical company in Latin America. Adium México also operates Adium Pro, a wholly-owned digital platform providing medical-scientific courses, clinical cases, webinars, and events to healthcare professionals.

The company pursues a dual business model: (1) proprietary and branded pharmaceutical product sales, including combination therapies and branded generics such as Tavor CR, Vesicare, Iltux, Tafirol, and Vartalon Compositum, distributed through authorized pharmacies and healthcare institutions; and (2) long-term licensing and distribution agreements with more than 10 multinational biotech and innovation companies (PharmaMar, Y-mAbs, BeiGene, Jazz Pharmaceuticals, Astellas Pharma, Debiopharm, and others), positioning Adium as the partner of choice for foreign innovators seeking pan-Latin American market access. Go-to-market is enterprise field sales via a specialized sales force targeting healthcare professionals and institutions, supported by a restricted-access healthcare professional portal, medical congresses, email marketing, and organic social channels. Manufacturing is governed by Quality by Design, GMP/GLP/GDP practices, and a pharmacovigilance system aligned with EMA and USFDA guidelines. In May 2024, the Mexican entity rebranded from Asofarma de México to Adium México to align with the broader Grupo Adium brand; the legal entity and operations remained unchanged.

Adium México firmographics

Firmographics
Name
Adium México
Legal name
Asofarma de México, S.A. de C.V.
Website
https://adium.com.mx
Company type
Private
Founded year
1974
Operating status
Operating
Headcount range
251–500 employees
Short description
Adium México (legal entity Asofarma de México, S.A. de C.V.) is a pharmaceutical laboratory that develops, manufactures, and distributes branded prescription medications across 15 therapeutic areas, serving healthcare professionals and patients in Mexico as part of Grupo Adium, a Latin American pharmaceutical group operating in 18 countries.
Ownership category
akta.pro rank

Adium México industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRAOAHAA
Prescription Pharmaceutical (Rx) Wholesale Distribution

Keywords

  • Pharmaceutical manufacturing
  • Prescription medications
  • Therapeutic products
  • Healthcare distribution
  • Biotech licensing

Where Adium México is headquartered

Location

Headquarters

HQ city
México
HQ country
Colombia
HQ region
Latin America

Offices3 records

Markets served

Adium México business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Sale of proprietary and licensed pharmaceutical products across multiple therapeutic areas including cardiology, diabetes, oncology, and rare diseases
  2. Licensing and Distribution: Licensing agreements with global biotech and innovation companies for promotion and distribution of their products throughout Latin America

Pricing tiers

ModelBillingPrice
OtherOtherPrescription pharmaceutical products

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Adium México product offering

Product offering

Core offering

Adium México is a pharmaceutical laboratory that develops, manufactures, and commercializes a broad portfolio of prescription medications across 15 therapeutic areas including cardiology, diabetes, oncology, rare diseases, neurology, and gynecology. The company distributes both proprietary products and those licensed from global biotech partners to healthcare professionals and institutions in Mexico, supported by a specialized sales force, GMP-certified manufacturing, and pharmacovigilance systems aligned with international regulatory standards.

Product overview

Adium México is a pharmaceutical laboratory offering a broad portfolio of therapeutic products organized across 15 therapeutic areas: Cardiology, Diabetes, Analgesia, Rare Diseases, Gastroenterology, Gynecology, Hematology, Immunology, Neurology, Obesity, Oncology, Osteoarticular, Osteoporosis, Psychiatry, and Urology. The company also operates Adium Pro, a digital platform for medical-scientific content. Products include both branded medications (Tavor CR, Vesicare, Iltux, Tafirol, Vartalon, etc.) and combination therapies. The portfolio spans over 50 years of experience, offering innovative and high-quality therapeutic solutions to physicians and patients in Mexico and Latin America.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cardiology Portfolio Pharmaceutical products for the treatment of hypertension, hypercholesterolemia, and anticoagulation, addressing cardiovascular disease as a leading cause of death in Latin America. Prescribed by cardiology specialists.
  • Diabetes Portfolio Products for treatment of Diabetes Type I and Type II, addressing a leading cause of death and disability in Latin America. Includes combination therapies such as Vidagliptina/Metformina.
  • Oncology Portfolio Broad portfolio of medications for different types of cancer affecting lung, breast, pancreas, and bile ducts, including tamoxifen-based therapy. Distributed through licensing partnerships with global biotech companies.
  • Rare Diseases Portfolio Medicines for rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis.
  • Adium Pro Medical-scientific content platform for healthcare professionals providing access to courses, articles, clinical cases, events, webinars, and continuing medical education resources.
  • Licensing and Distribution Partnerships Long-term licensing and distribution agreements with over 10 multinational biotech and innovation companies including PharmaMar, Y-mAbs, BeiGene, Jazz Pharmaceuticals, Astellas Pharma, and Debiopharm, enabling promotion and distribution of their innovative products across Latin America.

Quantifiable outcome

  • 42% of waste recycled in 2023
  • +3 more outcomes

Companies that use Adium México

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Adium México technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Adium México partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • PharmaMarcoreStrategic or Co-development PartnerLicensing agreement for innovative pharmaceutical products, enabling distribution of advanced therapies in Latin America through Adium's regional presence and commercial capabilities.
  • Y-mAbscoreStrategic or Co-development PartnerLicensing partnership for pediatric oncology and other specialty therapeutic areas, leveraging Adium's regional commercial infrastructure.
  • BeiGenecoreStrategic or Co-development PartnerGlobal biotech partnership for innovative oncology treatments, distributed through Adium's commercial network across Latin America.
  • Jazz PharmaceuticalscoreStrategic or Co-development PartnerLicensing partnership for specialty pharmaceuticals, utilizing Adium's market access expertise and regulatory capabilities in the region.
  • Astellas PharmacoreStrategic or Co-development PartnerPartnership for innovative pharmaceutical products, leveraging Adium's regional presence and specialized sales force.
  • DebiopharmcoreStrategic or Co-development PartnerLicensing partnership for specialty therapeutics, distributed through Adium's established commercial channels in Latin America.
  • Additional Global Innovation PartnerscoreStrategic or Co-development PartnerAdium holds long-term licensing agreements with more than 10 multinational innovation companies, positioning the company as the partner of choice for pharmaceutical expansion into Latin America.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Adium México competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Sanofi is a global pharmaceutical incumbent operating in cardiovascular, diabetes, oncology, rare disease and vaccines across Latin America. Comparable as a broad-portfolio competitor in the same therapeutic categories Adium addresses, though at materially larger scale and with proprietary global R&D.
  • Novartis AG: Novartis is a global branded pharmaceutical incumbent with an established commercial presence across Latin America, overlapping with Adium in cardiology, oncology, neurology and immunology therapeutic areas. It competes broadly but is not specialty-focused on the LatAm mid-tier market Adium targets.

Direct peers

  • Eurofarma Laboratórios: Eurofarma is a Brazilian privately held pharmaceutical company with manufacturing operations across Latin America and a portfolio spanning multiple therapeutic areas including specialty, generics and OTC — directly comparable to Adium México in scale, LatAm geographic footprint, and broad-therapeutic-area pharmaceutical commercialization model.
  • Laboratorios Bagó: Bagó is an Argentine-founded multinational pharmaceutical group with operations across Latin America, manufacturing branded specialty and OTC products. Its pan-regional LatAm manufacturing and commercial model is closely comparable to Adium's group-level footprint.
  • Aché Laboratórios Farmacêuticos: Aché is a top-five Brazilian pharmaceutical company with branded generics, prescription, and OTC products plus a meaningful oncology franchise. Like Adium, Aché operates manufacturing in multiple Latin American countries with multi-therapeutic-area coverage and is a comparable regional scale player.
  • EMS Pharma: EMS is one of the largest Brazilian pharmaceutical manufacturers with leading market share in Brazil and a broad generics-plus-branded portfolio. It is a direct competitor to Adium in the Latin American prescription pharmaceutical market, particularly in Brazil and cross-border specialty categories.
  • Biolab Farmacêutica: Biolab is a Brazilian specialty pharmaceutical company with strong presence in cardiology, women's health and central nervous system therapeutics. Its therapeutic mix, LatAm regional focus and licensing-driven growth model closely resemble Adium's strategy.
  • Siegfried Holding: Siegfried is a Swiss pharmaceutical manufacturer specializing in contract development and manufacturing for branded and generic drugs globally, including Latin America. Comparable to Adium in the manufacturing-for-license-partners and finished-dose pharmaceutical production model.

Regional players

  • Laboratorios Liomont: Liomont is a Mexican pharmaceutical manufacturer of branded generics and specialty products, operating mainly in Mexico but exporting regionally. It is comparable to Adium México on therapeutic-area breadth and Mexico-centric manufacturing, though smaller in geographic reach.
  • Genomma Lab Internacional: Genomma Lab is a Mexico-headquartered pharmaceutical company listed on the Mexican Stock Exchange with a portfolio spanning OTC, personal care and branded generics across Latin America. It is the most direct publicly traded Mexican pharma comparable to Adium México in therapeutic breadth and LatAm commercial footprint.

Market position

Strengths3 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Adium México social profiles

Digital presence

Adium México compliance and trust

Trust signal

Compliance2 records

Adium México financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adium México leadership team

Management profile

Number of profiles

Profiles1 record

Adium México subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Adium México funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adium México M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adium México

What does Adium México do?

Adium México is a pharmaceutical laboratory that develops, manufactures, and commercializes a broad portfolio of prescription medications across 15 therapeutic areas including cardiology, diabetes, oncology, rare diseases, neurology, and gynecology. The company distributes both proprietary products and those licensed from global biotech partners to healthcare professionals and institutions in Mexico, supported by a specialized sales force, GMP-certified manufacturing, and pharmacovigilance systems aligned with international regulatory standards.

Is Adium México a public or private company?

Adium México is a private company. It is classified as corporate owned and is currently operating.

When was Adium México founded?

Adium México was founded in 1974. It employs 251 to 500 people.

Where is Adium México based?

Adium México is headquartered in México, Colombia, in the Latin America region.

How does Adium México make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Distribution.

Who are Adium México's main competitors?

Broad incumbents on record are Sanofi and Novartis AG. Direct peers are Eurofarma Laboratórios, Laboratorios Bagó, Aché Laboratórios Farmacêuticos, EMS Pharma, Biolab Farmacêutica and Siegfried Holding. Regional players are Laboratorios Liomont and Genomma Lab Internacional.

Does Adium México have an API?

No public API is recorded for Adium México.

What industry is Adium México in?

Adium México's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales